Rubius Therapeutics, Inc.
RUBYDelisted Mar 28, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001709401
Rubius Therapeutics, Inc. was delisted on Mar 28, 2023; its insiders filed their last Form 4 on Feb 27, 2023; 42 institutions reported holding it in 13F filings for Q4 2022, worth $11.2M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 42
- Q4 2022, −19 vs. previous quarter
- 13F value
- $11.2M
- Reported value at the end of Q4 2022
- Superinvestors holding
- 0
- At the end of Q4 2022
Superinvestors holding RUBY, Q4 2022
No superinvestor reported holding RUBY at the end of Q4 2022.
Latest insider trades
Open-market purchases and sales by Rubius Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2023 (view filing)6:08 PM ET | Feb 24 | 3 days | Appelhans DannielleCEO and President | SSale | −10.4K | $0.1274 | −$1.32K | −100.0%0 after | |
| Feb 1, 2023 (view filing)9:41 PM ET | Feb 1 | Same day | Cagnoni Pablo JDirector | SSale | −8.45K | $0.25 | −$2.11K | −11.3%66.1K after | |
| Feb 1, 2023 (view filing)9:40 PM ET | Feb 1 | Same day | Appelhans DannielleCEO and President | SSale | −3.88K | $0.25 | −$969.5 | −27.2%10.4K after | |
| Jan 31, 2023 (view filing)9:51 PM ET | Jan 31 | Same day | Cagnoni Pablo JDirector | SSale | −7.24K | $0.241 | −$1.74K | −8.9%74.5K after | |
| Jan 31, 2023 (view filing)9:50 PM ET | Jan 31 | Same day | Turka Laurence A.Chief Scientific Officer | SSale | −2.59K | $0.24 | −$622.32 | −12.4%18.4K after | |
| Aug 12, 2022 (view filing) | Aug 10 | 2 days | Appelhans DannielleChief Operating Officer | SSale | −5.74K | $0.80 | −$4.59K | −45.9%6.76K after | |
| Apr 22, 2022 (view filing) | Apr 21 | 1 day | Epstein David RDirector | PPurchase | +30.0K | $1.44 | +$43.2K | +0.6%4.72M after | |
| Feb 1, 2022 (view filing) | Feb 1 | Same day | Cagnoni Pablo JCEO and President | SSale | −6.73K | $6.57 | −$44.2K | −15.9%35.5K after | |
| Feb 1, 2022 (view filing) | Feb 1 | Same day | Keson-Brookes MaikenCLO & Corp. Secretary | SSale | −2.73K | $6.57 | −$17.9K | −33.8%5.34K after | |
| Feb 1, 2022 (view filing) | Feb 1 | Same day | Turka Laurence A.Chief Scientific Officer | SSale | −2.52K | $6.57 | −$16.5K | −33.8%4.92K after |
Top 10 13F holders, Q4 2022
The largest institutional positions in Rubius Therapeutics, Inc. at the end of Q4 2022; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 38,506,526 | $6.55M | 0.21% | 00.0% | Unchanged |
| FMR LLC | 12,376,153 | $2.13M | 0.00% | −1,081,346−8.0% | Reduced |
| Baillie Gifford & Co | 4,869,126 | $838.0K | 0.00% | +15,353+0.3% | Added |
| Artal Group S.A. | 2,042,666 | $357.0K | 0.02% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,676,669 | $293.4K | 0.00% | −28,619−1.7% | Reduced |
| Acadian Asset Management LLC | 1,277,196 | $222.0K | 0.00% | +614,522+92.7% | Added |
| BlackRock Inc. | 1,197,501 | $209.6K | 0.00% | −390,426−24.6% | Reduced |
| HarbourVest Partners LLC | 986,878 | $172.7K | 0.06% | 00.0% | Unchanged |
| State of Michigan Retirement System | 640,000 | $110.1K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 412,218 | $70.0K | 0.00% | −23,428−5.4% | Reduced |